High Glucose Uptake E. Coli Strain
- Detailed Technology Description
- In the push towards biofuels and biodegradable products, efficient growth within plant-based substrates will become more prevalent. Using a new strain design method, UC San Diego inventors have invented a new strain of E. coli that experiences high levels of glucose uptake fermentatively relative to other known strains with a weight yield of 98.4 ± 3.4 percent and with an uptake rate of 43.1 ± 1.3 mmol gDW-1 hr-1. An additional advantage is the strain’s ability to uptake xylose (though not at the same high rate). The utility of this new strain is in higher rate fermentation processes. The increase in the uptake of glucose potentially provides an increase in the production rate of D-lactic acid or other desired compounds. The production of D-lactic acid is a pre-cursor step to the production of biodegradable plastics (i.e. polylactic acid). The research leading up to this invention is described in papers located at http://gcrg.ucsd.edu/Researchers/Feist_Publications. The design methodology for this strain can also be applied to produce other strains with other attractive properties.
- Supplementary Information
- Inventor: Brenner, Charles M.
Priority Number: US8197807B2
IPC Current: A61K003845 | A61K00317076 | A61P003500 | C07H001700 | C07H002104 | C12N000904 | C12N000912
US Class: 4240945 | 435015 | 514025 | 514045
Assignee Applicant: Trustees of Dartmouth College,Hanover
Title: Nicotinamide riboside kinase compositions and methods for using the same
Usefulness: Nicotinamide riboside kinase compositions and methods for using the same
Summary: The nucleic acid, polypeptide, vector, and methods are useful for preventing or treating a disease or condition associated with the nicotinamide riboside kinase pathway, e.g. cancers (e.g. pancreatic cancer, endometrial cancer, small cell and non-small cell cancer of the lung, squamous cell cancer of the head and neck, bladder, ovarian, cervical, breast, renal, CNS, and colon cancers, myeloid and lymphocytic leukemia, lymphoma, hepatic tumors, medullary thyroid carcinoma, multiple myeloma, melanoma, retinoblastoma, and sarcomas of the soft tissue and bone), lipid disorders (e.g., dyslipidemia, hypercholesterolemia, or hyperlipidemia), stroke, neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, and multiple sclerosis), neurotoxicity as observed with chemotherapies, Candida glabrata infection, and the general health declines associated with aging
Novelty: New isolated eukaryotic nucleic acid encoding nicotinamide riboside kinase polypeptide, useful for preventing or treating a disease or condition associated with nicotinamide riboside kinase pathway, e.g. cancers
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Application No.
- 9932598
- Others
-
Related cases
SD2009-239
Tech ID/UC Case
19878/2009-238-0
Related Cases
2009-238-0
- *Abstract
-
None
- *IP Issue Date
- Apr 3, 2018
- *Principal Investigator
-
Name: Adam Feist
Department:
Name: Bernhard Palsson
Department:
- Country/Region
- USA
For more information, please click Here
